Best of Hematology and Breast Cancer 2025, Des Moines

Des Moines, IA US
March 29, 2025

Overview

The Best of Hematology and Breast Cancer 2025 conference in Des Moines is a CME-accredited, in-person event providing healthcare professionals with the latest updates in managing hematology and breast cancer. Drawing insights from the 66th ASH Annual Meeting (ASH24) and the San Antonio Breast Cancer Symposium (SABCS24), the conference features expert presentations on recent research and its clinical implications.

Focusing on a multidisciplinary approach, the event aims to integrate new advancements into patient-centered care. Designed for physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other professionals, attendees will engage with colleagues and experts to critically evaluate data and improve patient outcomes.

The Best of Hematology and Breast Cancer 2025, Des Moines, is an educational activity planned by the Binaytara Foundation. Neither Binaytara Foundation nor this activity are affiliated with the American Society of Hematology (ASH) or the San Antonio Breast Cancer Symposium (SABCS).

Target Audience

  • Medical Oncologists
  • Surgical Oncologists
  • Radiation Oncologists
  • Oncology Fellows
  • Oncology Nurses
  • Nurse Practitioners
  • Physician Assistants
  • Oncology Pharmacists

Organizing Committee

Conference Director:

  • Binay Shah, MD, MHA Binaytara Foundation

Conference Co-Chairs:

  • Kartik Anand, MD - The Iowa Clinic
  • Matthew Lunning, DO, FACP - University of Nebraska Medical Center
  • Vishal Vashistha, MD - VA Iowa City Health Care

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Summarize the latest updates from ASH24 and SABCS24, focusing on their implications for clinical practice in managing hematologic disorders and breast cancer.
  • Assess new therapeutic options for benign and malignant hematologic disorders and breast cancer, including appropriate indications and contraindications presented at ASH24 and SABCS24.
  • Examine the study design, primary endpoints, and impact of recent and ongoing clinical trials from ASH24 and SABCS24 that have influenced current standards of care.
  • Incorporate evolving diagnostic, prognostic, and therapeutic strategies from ASH24 and SABCS24 into patient management for hematologic disorders and breast cancer.
  • Apply emerging data from clinical trials and updated expert guidelines from ASH24 and SABCS24 to individualize patient management strategies.

Hotel Room Reservation

A limited number of guestrooms are reserved at the Des Moines Marriott Downtown Hotel for the participants of this meeting at a discounted rate of $159 per night. The room rate does not include any additional fees or applicable taxes.

CUTOFF - Thursday, March 6, 2025.

Parking

Off-site parking available at City of Des Moines Parking Garage 4th and Grand (0.1 miles)

Valet parking available at $35.

 

Course summary
Available credit: 
  • 6.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.75 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-009-L01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

    ACPE Pharmacy
  • 6.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.75 Contact Hours.
Course opens: 
08/27/2024
Course expires: 
05/28/2025
Event starts: 
03/29/2025 - 8:00am PDT
Event ends: 
03/29/2025 - 4:35pm PDT
Cost:
$150.00

Program

Saturday, March 29, 2025

All times listed in Central Daylight Time (CDT)

07:00 AM – 08:00 AM  Registration, Exhibits & Breakfast


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:30 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities


08:30 AM – 09:30 AM  Session 1: Tumor Board-Style Case-Based Discussion: Benign Hematology

Session Chair: Krishna Gundabolu, MD

08:30 AM – 09:00 AM  PNH and TTP-HUS - Alex Nester, MD

09:00 AM – 09:30 AM  Bleeding and Clotting Disorder - George Scaria, MD


09:30 AM – 10:30 AM  Session 2: Leukemia

Session Chair: James Armitage, MD

09:30 AM – 10:00 AM  Acute Myeloid Leukemia - Prajwal Dhakal, MBBS

10:00 AM – 10:30 AM  Chronic Lymphocytic Leukemia - Nanmeng Yu, MD


10:30 AM – 11:00 AM  Break & Exhibits


11:00 AM – 12:00 PM  Session 3: Lymphoid Malignancies

Session Chair: Christopher Strouse, MD

11:00 AM – 11:30 AM  Multiple Myeloma - Hira Shaikh, MD

11:30 AM – 12:00 PM  B-Cell Lymphoma - Tara Graff, MD


12:00 PM – 01:00 PM  Lunch & Exhibits

Product Theater Sponsored by JNJ

Title: CART-4 | Speaker: Dr. Daanish Hoda

*This is a non-CME activity*


01:00 PM – 02:00 PM  Session 4: Hematologic Malignancies

Session Chair: Matthew Lunning, DO, FACP

01:00 PM – 01:30 PM  Myeloproliferative Neoplasms - Grerk Sutamtewagul, MD

01:30 PM – 02:00 PM  Cellular Therapy - Matthew Lunning, DO, FACP


02:00 PM – 02:15 PM  Break & Exhibits


02:15 PM – 03:45 PM  Session 5: Updates in Management of Breast Cancer

Session Chair: Sneha Phadke, MD

02:15 PM – 02:45 PM  HER2 Positive Breast Cancer - Meghana Kesireddy, MD

02:45 PM – 03:15 PM  Triple Negative and HER2 Low Breast Cancer - Dean Elhag, MD

03:15 PM – 03:45 PM  ER/PR Positive Breast Cancer - Sneha Phadke, DO, MPH


03:45 PM – 05:00 PM  Session 6: Tumor Board Style Case-Based Discussion: Breast Cancer

Session Chair: Kartik Anand, MD

03:45 PM – 04:05 PM  Metaplastic Breast Cancer - Kartik Anand, MD

04:05 PM – 04:25 PM  Surgery: Less is More - Juan Santamaria, MD, FACS, FSSO

04:25 PM – 04:45 PM  Radiation: Keep it Simple - Arshin Sheybani, MD

04:45 PM – 05:00 PM  Panel Discussion


05:00 PM  Adjourn

Venue

Renaissance Des Moines Savery Hotel
401 Locust St
Des Moines, IA 50309
United States

Hotel Room Reservation

A limited number of guestrooms are reserved at the Renaissance Des Moines Savery Hotel for the participants of this meeting at a discounted rate of $159 per night. The room rate does not include any additional fees or applicable taxes.

CUTOFF - Thursday, March 6, 2025.

Parking

Off-site parking available at City of Des Moines Parking Garage 4th and Grand (0.1 miles)

Valet parking available at $35.

Faculty

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Conference Chair(s)

Kartik Anand, MD

has a financial relationship (Stock) with Crispr therapeutics;.
has a financial relationship (Other) with Biotheranostics, Inc;.
has a financial relationship (Stock Options) with Eli Lilly;.

Matthew Lunning, Matt Lunning, D.O., F.A.C.P.

has a financial relationship (Professional Services) with Nurix;.
has a financial relationship (Professional Services) with SeaGen;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with EUSA;.
has a financial relationship (Professional Services) with InstilBio;.
has a financial relationship (Professional Services) with Loxo;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Acrotech;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with GenMab;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with Morphosys;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Astellas;.
has a financial relationship (Grant Or Contract) with Curis;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Miltenyi;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Professional Services) with CRISPR;.
has a financial relationship (Professional Services) with Fate Therapetuics;.
has a financial relationship (Professional Services) with Ipsen;.

Vishal Vashistha, M.D.

has no relevant financial relationships to disclose at this time.
Session Chair(s)

Kartik Anand, MD

has a financial relationship (Stock Options) with Eli Lilly;.
has a financial relationship (Stock) with Crispr therapeutics;.
has a financial relationship (Other) with Biotheranostics, Inc;.

Jim Armitage, M.D.

has a financial relationship (Stock Options) with cardiff oncology;.

KRISHNA GUNDABOLU, MD; MS; FACP

has no relevant financial relationships to disclose at this time.

Matthew Lunning, Matt Lunning, D.O., F.A.C.P.

has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Acrotech;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with GenMab;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with Morphosys;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Astellas;.
has a financial relationship (Grant Or Contract) with Curis;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Miltenyi;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Professional Services) with CRISPR;.
has a financial relationship (Professional Services) with Fate Therapetuics;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with Nurix;.
has a financial relationship (Professional Services) with SeaGen;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with EUSA;.
has a financial relationship (Professional Services) with InstilBio;.
has a financial relationship (Professional Services) with Loxo;.

Sneha Phadke, DO, MPH

has a financial relationship (Professional Services) with Starling Pharmaceuticals;.

Christopher Strouse, MD

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Prajwal Dhakal

has a financial relationship (Other) with Stemline Therapeutics;.
has a financial relationship (Other) with Abbvie/Genetech Pharmaceutical;.

Dean Elhag, MD

has no relevant financial relationships to disclose at this time.

Tara Graff, DO MS

has a financial relationship (Independent contractor) with Adaptive;.
has a financial relationship (Independent contractor) with Genmab;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Independent contractor) with Cellectar;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Independent contractor) with AZ;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with ADC Therapeutics;.
has a financial relationship (Independent contractor) with AbbVie;.
has a financial relationship (Independent contractor) with KITE;.
has a financial relationship (Independent contractor) with Genetench;.

Meghana Kesireddy, MBBS; Assistant Professor

has no relevant financial relationships to disclose at this time.

Alex Nester, MD

has a financial relationship (Professional Services) with Bayer;.

Sneha Phadke, DO, MPH

has a financial relationship (Professional Services) with Starling Pharmaceuticals;.

Hira Shaikh, MD

has a financial relationship (Grant Or Contract) with Astrezeneca;.

Arshin Sheybani, MD

has no relevant financial relationships to disclose at this time.

Grerk Sutamtewagul, Grerk Sutamtewagul, MD.

has no relevant financial relationships to disclose at this time.

Nanmeng Yu, MD, PhD

has no relevant financial relationships to disclose at this time.
Case Presenter(s)

Kartik Anand, MD

has a financial relationship (Other) with Biotheranostics, Inc;.
has a financial relationship (Stock Options) with Eli Lilly;.
has a financial relationship (Stock) with Crispr therapeutics;.

Juan Santamaria, MD FACS FSSO

has a financial relationship (Other) with Stryker;.
has a financial relationship (Other) with Molli;.

George Scaria, MD, PhD

has no relevant financial relationships to disclose at this time.

Arshin Sheybani, MD

has no relevant financial relationships to disclose at this time.

Accreditation

Acknowledgement of Commercial Support

This activity is supported with Independent Medical Education grants from:

  • Exact Sciences
  • Incyte

Available Credit

  • 6.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.75 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-009-L01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

    ACPE Pharmacy
  • 6.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.75 Contact Hours.

Exhibitors

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Register/Take course

Price

Cost:
$150.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.